stockrowXencor, Inc.
XNCR Healthcare Biotechnology
Xencor, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $125.6 million, up 13.7% from fiscal 2024.
- Revenue
- +17.5%
- EPS
- +29.3%
- Free cash flow
- −52.9%
Quarter to June 2026, against a year earlier
Follow XNCR
Alert me
Xencor, Inc. (XNCR) EV/FCF
As of 5 November 2026, Xencor, Inc. (XNCR) trades at a EV/FCF of −10.8×. Over the past ten years it has ranged from −133× (February 2021) to 107× (September 2016); the current reading is higher than 38% of that period.
EV/FCF, daily
Embed this chart
Annual newest first
| Period | EV/FCF | Change |
|---|---|---|
| FY2025 | −5.1× | — |
| FY2024 | −5.5× | — |
| FY2023 | −9.7× | — |
| FY2022 | −52.0× | — |
| FY2021 | −62.2× | — |
| FY2020 | −101× | — |
| FY2019 | 26.7× | — |
| FY2018 | −18.6× | — |
| FY2017 | −20.6× | — |
| FY2016 | 9.8× | (52.28%) |
Quarterly newest first
| Period | EV/FCF | Change |
|---|---|---|
| Jun 2026 | −4.2× | — |
| Mar 2026 | −3.1× | — |
| Dec 2025 | −5.1× | — |
| Sep 2025 | −4.0× | — |
| 39 more quarters | Free account |
Against its own ten years
EV/FCF against peers
| Company | EV/FCF |
|---|---|
| MBX MBX Biosciences, Inc. compare | −22.3× |
| NAMS NewAmsterdam Pharma Company N.V. compare | −11.4× |
| XNCR Xencor, Inc. | −10.8× |
| ZLAB Zai Lab Limited Unsponsored ADR compare | −10.5× |
| PHVS Pharvaris N.V. compare | −10.5× |
| BEAM Beam Therapeutics Inc. compare | −4.5× |
| RXRX Recursion Pharmaceuticals, Inc. compare | −4.3× |
| RCUS Arcus Biosciences, Inc. compare | −3.7× |
| ADMA ADMA Biologics Inc compare | 25.2× |
What EV/FCF is
EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))
More on XNCR
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement